{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1361699995705149952.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1002/pbc.23062"}},{"identifier":{"@type":"URI","@value":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fpbc.23062"}},{"identifier":{"@type":"URI","@value":"https://onlinelibrary.wiley.com/doi/pdf/10.1002/pbc.23062"}}],"dc:title":[{"@value":"Safety and efficacy of tandem <sup>131</sup>I‐metaiodobenzylguanidine infusions in relapsed/refractory neuroblastoma"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Targeted radiotherapy with <jats:sup>131</jats:sup>I‐Metaiodobenzylguanidine (<jats:sup>131</jats:sup>I‐MIBG) is safe and effective therapy for patients with relapsed neuroblastoma, but anti‐tumor activity is sometimes transient. The goal of this study was to determine the safety and efficacy of early (<100 days) second <jats:sup>131</jats:sup>I‐MIBG treatment following an effective initial treatment.</jats:p></jats:sec><jats:sec><jats:title>Procedures</jats:title><jats:p>After an initial infusion of 18 mCi/kg <jats:sup>131</jats:sup>I‐MIBG, patients with tumor response or stable disease (SD), and available hematopoietic stem cell product, were eligible for additional <jats:sup>131</jats:sup>I‐MIBG therapy. Residual thrombocytopenia did not preclude patients from receiving additional treatment. Subsequent treatment was administered a minimum of 6 weeks and maximum 100 days from initial infusion, and subjects could receive subsequent therapy if the same criteria were met.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Seventy‐six heavily pretreated patients (median 4 prior chemotherapy regimens, range 1–8) with relapsed neuroblastoma were treated with <jats:sup>131</jats:sup>I‐MIBG. Response rate to the first infusion was 30%, with 49% showing SD. Response rate among the 41 patients receiving a subsequent second infusion was 29%. After two treatments, 39% of patients experienced a reduction in overall disease burden. Four of five complete responses (CRs) to the initial infusion were maintained, despite all five having disease readily apparent on immediate post‐second treatment <jats:sup>131</jats:sup>I‐MIBG scanning. Hematologic toxicity was managed with early PBSC support after the second therapy (median: 15 days).</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Early second <jats:sup>131</jats:sup>I‐MIBG safely reduces disease burden in patients with relapsed neuroblastoma. Patients with CR by conventional <jats:sup>123</jats:sup>I‐MIBG scintigraphy may have substantial disease burden apparent on high‐dose <jats:sup>131</jats:sup>I‐MIBG scintigraphy, supporting consolidation with subsequent <jats:sup>131</jats:sup>I‐MIBG therapy in cases of apparent complete remission. Pediatr Blood Cancer 2011; 57: 1124–1129. © 2011 Wiley Periodicals, Inc.</jats:p></jats:sec>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1381699995705149954","@type":"Researcher","foaf:name":[{"@value":"Kelsey Johnson"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699995705149955","@type":"Researcher","foaf:name":[{"@value":"Barbara McGlynn"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699995705149956","@type":"Researcher","foaf:name":[{"@value":"Jennifer Saggio"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699995705149957","@type":"Researcher","foaf:name":[{"@value":"Diane Baniewicz"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699995705149952","@type":"Researcher","foaf:name":[{"@value":"Hongming Zhuang"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699995705149958","@type":"Researcher","foaf:name":[{"@value":"John M. Maris"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699995705149953","@type":"Researcher","foaf:name":[{"@value":"Yael P. Mosse"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"15455009"},{"@type":"EISSN","@value":"15455017"}],"prism:publicationName":[{"@value":"Pediatric Blood & Cancer"}],"dc:publisher":[{"@value":"Wiley"}],"prism:publicationDate":"2011-04-14","prism:volume":"57","prism:number":"7","prism:startingPage":"1124","prism:endingPage":"1129"},"reviewed":"false","dc:rights":["http://onlinelibrary.wiley.com/termsAndConditions#vor"],"url":[{"@id":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fpbc.23062"},{"@id":"https://onlinelibrary.wiley.com/doi/pdf/10.1002/pbc.23062"}],"createdAt":"2011-04-14","modifiedAt":"2023-10-09","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1050001335983941248","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Iodine-131 metaiodobenzylguanidine therapy for neuroblastoma: Reports so far and future perspective"}]},{"@id":"https://cir.nii.ac.jp/crid/1360009142476394880","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Diagnostic Use of Post-therapy 131I-Meta-Iodobenzylguanidine Scintigraphy in Consolidation Therapy for Children with High-Risk Neuroblastoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1360290617881508352","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"High-dose 131I-mIBG as consolidation therapy in pediatric patients with relapsed neuroblastoma and ganglioneuroblastoma: the Japanese experience"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1002/pbc.23062"},{"@type":"CROSSREF","@value":"10.3390/diagnostics10090663_references_DOI_F8TyjpdSPWZSVgExNGYphUO40QO"},{"@type":"CROSSREF","@value":"10.1007/s12149-020-01514-2_references_DOI_F8TyjpdSPWZSVgExNGYphUO40QO"},{"@type":"CROSSREF","@value":"10.1155/2015/189135_references_DOI_F8TyjpdSPWZSVgExNGYphUO40QO"}]}